10-K: Hepion Pharmaceuticals Faces Going Concern Doubt, Pivots to Diagnostics

Hepion Pharmaceuticals reports significant losses and going concern doubt, pivoting from drug development to diagnostic tests after winding down its lead clinical trial and delisting from Nasdaq.

Summary

• The company incurred an accumulated deficit of $246.1 million as of December 31, 2025, and reported a net loss of $8.3 million for the year, an improvement from $13.2 million in 2024.
• Substantial doubt exists regarding the company's ability to continue as a going concern within one year without additional capital.
• The ASCEND-NASH clinical trial for rencofilstat (formerly CRV431) was wound down in April 2024 and closed in August 2024 due to insufficient funding.
• A merger agreement with Pharma Two B Ltd., entered into on July 19, 2024, was terminated on December 10, 2024, after Nasdaq would not exclude historical losses from its burn rate calculation.
• On January 23, 2025, the company completed a public offering, raising $9.0 million in gross proceeds through the sale of common stock and warrants, used in part to repay notes payable.
• On May 9, 2025, the company in-licensed diagnostic tests for celiac disease, respiratory multiplex, H. pylori, and hepatocellular carcinoma (HCC) from New Day Diagnostics LLC, paying $525,000 cash and $270,629 in common stock, with potential future milestone payments up to $17.15 million and royalties.
• An asset impairment loss of $402,746 was recorded for the New Day Diagnostics license due to delayed timing to market and insufficient projected cash flow to recover allocated costs within the initial two-year license term.
• On May 26, 2025, the company sold all patent assets, know-how, clinical trial data, and drug product related to Rencofilstat to Panetta Partners Limited for a nominal amount, with contingent value rights (CVR) for stockholders up to $4.5 million based on future regulatory approvals and sales milestones.
• On February 25, 2026, the company licensed liver disease diagnostic assets from Cirna Diagnostics, LLC, involving an upfront payment of $50,000, up to $2.35 million in milestone payments, up to $4.5 million in sales milestone payments, and low single-digit royalties.
• The company's common stock was delisted from Nasdaq effective May 13, 2025, and transitioned to the OTCQB Venture Market on June 25, 2025.
• Management identified material weaknesses in internal control over financial reporting as of December 31, 2025, related to control environment, period-end financial close, and income tax provision processes.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing with a highly negative sentiment due to the explicit 'going concern' doubt, the termination of the primary drug development program, the failure of a significant merger, Nasdaq delisting, and identified material weaknesses in internal controls, despite some cost reductions and a strategic pivot to diagnostics.

Positives

• Net loss decreased to $8.3 million in 2025 from $13.2 million in 2024, indicating a reduction in overall losses.
• Research and development expenses significantly decreased by $11.4 million, from $11.8 million in 2024 to $0.4 million in 2025, primarily due to the wind-down of the ASCEND-NASH clinical trial.
• General and administrative expenses decreased by $4.2 million, from $7.5 million in 2024 to $3.3 million in 2025, reflecting cost-cutting measures.
• Working capital increased by $4.3 million, from a deficit of $1.5 million in 2024 to a positive $2.8 million in 2025, primarily due to proceeds from equity issuance.
• The company successfully raised $9.0 million in gross proceeds from a public offering in January 2025, which was used to repay indebtedness and fund general corporate purposes.
• Strategic pivot to medical diagnostics through new licensing agreements with New Day Diagnostics LLC and Cirna Diagnostics, LLC, potentially opening new revenue streams in the EU and other eligible markets.

Negatives

• The company has incurred significant operating losses since inception, with an accumulated deficit of $246.1 million as of December 31, 2025.
• There is substantial doubt about the company's ability to continue as a going concern without securing additional capital.
• The lead drug therapy clinical trial (ASCEND-NASH for rencofilstat) was terminated due to insufficient funding, leading to the sale of all related patent assets for a nominal amount.
• A merger agreement with Pharma Two B Ltd. was terminated, indicating a failure to execute a significant strategic transaction.
• An asset impairment loss of $402,746 was recorded for the New Day Diagnostics license, suggesting challenges in the commercial viability or timing of these new diagnostic products.
• The company's common stock was delisted from Nasdaq and now trades on the less liquid OTCQB Venture Market, which can negatively impact stock price and investor confidence.
• Management identified material weaknesses in internal control over financial reporting as of December 31, 2025, raising concerns about financial reporting reliability.
• The company had only two employees as of December 31, 2025, following a strategic restructuring plan that included personnel reduction, which may impact operational capacity.

Risks

• Inability to raise substantial additional capital to continue as a going concern and fund planned operations.
• Uncertainty regarding estimates for expenses, cash use, timing of future cash needs, and anticipated capital requirements.
• Challenges in retaining officers, key employees, or directors.
• Potential for limited liquidity and trading of public securities, especially on the OTCQB Market.
• Inability to obtain and maintain regulatory approval for product candidates, and potential restrictions or warnings on approved products.
• Risks associated with pursuing research and development of other future product candidates.
• Uncertainty regarding the potential advantages, market acceptance, and clinical utility of product candidates.
• Dependence on the success of collaborations and partnerships with third parties.
• Inaccurate estimates regarding the potential market opportunity for product candidates.
• Lack of internal sales, marketing, and distribution capabilities and strategy.
• Inability to establish and maintain arrangements for the manufacture of product candidates.
• Intense competition from companies marketing or developing treatments for target indications.
• Challenges in protecting and enforcing intellectual property rights, and potential infringement claims from third parties.
• Future development and regulatory difficulties even if product candidates receive initial regulatory approval.
• Adverse effects from healthcare reform measures and other legislative initiatives.
• Failure to comply with Sarbanes-Oxley Act rules related to accounting controls and procedures, or discovery of additional material weaknesses.
• Provisions in the company's certificate of incorporation, by-laws, and Delaware law that may prevent or delay an acquisition.
• Future sales and issuances of common stock or rights to purchase common stock could result in additional dilution.
• Risk of securities class action litigation.
• Lack of research or reports from securities analysts could negatively impact stock price and trading volume.
• The company does not intend to pay cash dividends on common stock in the foreseeable future.
• Common stock being a 'penny stock' may make it more difficult for investors to sell shares.
• Trading on the OTCQB Market may have an unfavorable impact on stock price and liquidity.
• FINRA sales practice requirements may limit stockholders' ability to buy and sell common stock.
• Significant restrictions on the resale of common stock due to state blue sky laws.
• Disruptions to operations from information system failures, unsuccessful upgrades, or cyber-attacks.
• Business disruptions from pandemics, natural disasters, or other man-made events.
• Failure to enter into or maintain collaborations for commercialization of product candidates.
• Inadequate reimbursement or coverage from government and third-party payers for products.
• Inability to manufacture product candidates in commercial quantities.
• Unavailability of necessary materials for manufacturing on commercially reasonable terms.
• Significant product liability claims if uninsured or exceeding insurance coverage.
• Financial loss due to contamination or injury from hazardous materials.
• Inadequate funding for the FDA and other government agencies hindering timely product development and commercialization.
• Failure to maintain compliance with marketing authorization requirements for products and services.
• Product or service recalls could have a significant adverse impact.
• Misconduct or improper activities by employees, consultants, and collaborators, including non-compliance with regulatory standards and insider trading.
• Uncertainty of future Medicare payment rates for diagnostic laboratory testing services.
• Challenges in increasing the size of the organization to support clinical trials and commercialization.

Future Outlook

The company expects to continue incurring significant losses for the foreseeable future and will require substantial additional financing to fund operations, advance product candidates, and address material weaknesses in internal controls. It anticipates running out of available cash resources during the third quarter of 2026 without further funding. The strategic pivot to medical diagnostics aims to open new revenue streams, but the commercial viability and market acceptance of these new products are uncertain, and the company currently lacks internal commercialization capabilities.

Management Comments

• Management determined that disclosure controls and procedures and internal controls over financial reporting were ineffective as of December 31, 2025.
• We are committed to the remediation of the material weaknesses described above, as well as the continued improvement of our internal control over financial reporting.
• We need to raise additional capital in order to add additional personnel and implement additional internal control procedures.

Industry Context

StockSavvy.ai notes that Hepion Pharmaceuticals' pivot from drug development for chronic liver diseases (specifically NASH) to diagnostic tests reflects a common strategy for early-stage biopharmaceutical companies facing funding challenges and clinical trial setbacks. The diagnostic market, while competitive, may offer a potentially faster path to revenue compared to lengthy and costly drug development. However, the company's delisting from Nasdaq and move to the OTCQB market, coupled with an impairment loss on its initial diagnostic license, indicates significant hurdles in this new direction. The entry into the celiac, respiratory multiplex, H. pylori, and HCC diagnostic markets, and later liver disease diagnostics, places it in a crowded field with established players, requiring substantial investment in regulatory approval (especially for the U.S. market), manufacturing, and commercialization capabilities, which the company currently lacks.

Comparison to Industry Standards

• The company's accumulated deficit of $246.1 million and recurring losses are typical for early-stage biopharmaceutical companies engaged in R&D, but the termination of its lead clinical program due to funding issues is a significant setback compared to peers that successfully advance candidates.
• The delisting from Nasdaq and subsequent trading on the OTCQB Venture Market places the company in a less prestigious and less liquid market segment, contrasting sharply with established biopharma companies listed on major exchanges.
• The impairment loss on the New Day Diagnostics license ($402,746) suggests that the initial diagnostic assets may not meet commercial expectations or face unforeseen market entry challenges, which is a negative indicator compared to successful product launches in the diagnostics industry.
• The company's reliance on third-party manufacturers and lack of internal sales and marketing capabilities for its new diagnostic focus is a common model for smaller companies but presents execution risks compared to integrated industry leaders like Roche Diagnostics or Abbott Laboratories.
• The identified material weaknesses in internal control over financial reporting are below industry best practices and regulatory expectations for publicly traded companies, even smaller reporting companies, and could hinder investor confidence and future capital raises.

Management Changes

Corporate Governance

Legal Proceedings

• The company may become a party to various legal actions and complaints arising in the ordinary course of business, but currently has no reason to believe the outcome will have a material adverse effect on consolidated financial condition or results of operations.

Related Party Transactions

• A $600,000 loan was provided to Pharma Two B Ltd. on July 19, 2024, which was subsequently written off in 2024 after Pharma Two B filed for insolvency proceedings.
• The intellectual property license agreement with Cirna Diagnostics, LLC on February 25, 2026, involves Dr. Tim Block, a board member of the company, who is also a member of Cirna.

Stakeholder Impact

• Shareholders face significant dilution from recent and potential future equity raises, and the delisting from Nasdaq to OTCQB has negatively impacted liquidity and potentially share price.
• Employees experienced a reduction in force as part of a strategic restructuring, with only two employees remaining as of December 31, 2025, indicating job insecurity and a lean operational structure.
• Creditors (holders of notes payable) were repaid using proceeds from the January 2025 offering, but the company's going concern doubt poses future risks for new creditors.
• Customers and partners for the new diagnostic products face uncertainty regarding the company's long-term viability and ability to successfully commercialize and support these products.

Next Steps

• Obtain substantial additional financing to continue operations and fund the development of diagnostic product candidates.
• Advance the development and seek regulatory approval for in-licensed diagnostic tests (celiac, respiratory multiplex, H. pylori, HCC, and liver disease diagnostics).
• Address and remediate identified material weaknesses in internal control over financial reporting by increasing personnel and implementing additional procedures.
• Establish or partner for sales, marketing, and distribution capabilities for diagnostic products, particularly in the EU and other eligible markets.
• Manage and potentially achieve contingent value rights milestones for Rencofilstat for stockholders, though the company no longer owns the asset.

Key Dates

Recommendation

The company faces severe financial distress, explicitly stating 'substantial doubt' about its ability to continue as a going concern. Its primary drug development program failed due to lack of funding, a major merger was terminated, and its stock was delisted from Nasdaq. While a pivot to diagnostics and cost reductions are noted, an impairment loss on new diagnostic assets and identified material weaknesses in internal controls further compound the risks. The need for significant additional capital, coupled with a highly uncertain path to profitability and a less liquid trading market, makes the stock a high-risk investment with a strong likelihood of further value erosion.

Keywords

Medical Diagnostics, Liver Disease, Hepatocellular Carcinoma, Celiac Disease, Respiratory Multiplex, Helicobacter Pylori, SEC Filing, 10-K, Biopharmaceutical, Clinical Trials, Regulatory Approval, Going Concern, OTC Markets, Warrants, Equity Financing, Intellectual Property Licensing, Asset Impairment, Internal Controls